Bausch & Lomb has announced the European launch of enVista, a new glistening-free, hydrophobic acrylic intraocular lens product. Intraocular lenses, or IOLs, are surgically implanted into the lens capsule to replace the natural crystalline lens. The surgery is usually performed to replace natural lenses that have become clouded by cataracts, but it may also be an elective refractive surgery to adjust the eye’s optical power.
Glistening is thought to be the result of fluid accumulation in microscopic holes in the material used to construct IOLs. These microscopic holes are known as microvacuoles. Glistening is common with some hydrophobic acrylic IOL material. It causes a portion of the light entering the lens to be scattered in all directions, and it has been shown to negatively impact visual acuity. The visual consequence of glistening is still controversial; there have been no comprehensive studies on the effect of glistening.
Manufacturers clearly believe glistening is a potential problem, and some homogeneous hydrophobic acrylics are being marketed specifically as glistening-free materials for IOLs. The enVista lens lacks microvacuoles and is reported to eliminate glistening.
Bausch & Lomb recently introduced the new IOL at the 2011 Congress of the European Society of Cataract and Refractive Surgeons in Vienna, Austria. The product has been granted CE Mark approval, and the company is now seeking regulatory approval to sell enVista in non-European markets.
The enVista lens is Bausch & Lomb’s first hydrophobic IOL. In addition to a uniform surface that eliminates microvacuoles and glistening, the lens design is also reported to minimise posterior capsular opacification. Increased opacity is a common long-term post-surgical consequence of IOL implantation. The enVista lens is designed with a 360-degree square-edge barrier to provide an effective optic-haptic junction. This type of edge is known to reduce lens epithelial cell migration and has been associated with a reduced incidence of posterior capsular opacification.
Bausch & Lomb is known globally as a leading manufacturer of contact lenses and associated lens care products. The enVista lens expands the company’s existing IOL portfolio. Bausch & Lomb previously provided state of the art lens replacement through the 1.8 mm MICS Phaco system, which combined phacoemulsification and insertion of the Crystalens accommodating lens through a 1.8 mm incision, and the Akreos MICS lens for larger incisions. Bausch & Lomb also provides ophthalmic surgical devices and ophthalmic pharmaceuticals. The company is headquartered in Rochester, New York and employs more than 10,000 people.
Les writes for Personal Eyes about eye procedures, LASIK eye surgery, glaucoma & more.